HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketplace As Enforcer? FDA Cedes Onus To Litigants – Attorney

This article was originally published in The Rose Sheet

Executive Summary

Pointing to the uptick in consumer class actions targeting cosmetics claims and the lull in FDA enforcement action in the sector since the 2012 warning-letter blitz, Arent Fox partner Georgia Ravitz speculates that the agency is “letting the marketplace now scrutinize product label claims to determine whether they’re false or misleading.”

You may also be interested in...



Beauty Firms: Take Lessons From Food Industry In Class-Action Defense

Personal-care firms targeted with class actions over “natural” claims and other marketing can look to recent cases in the food sector for defense strategies that have proven effective, say two food and drug law attorneys. While suits targeting product claims are decidedly expensive and PR challenges, recent developments suggest that firms can strategize and invest to escape paying class damages.

Regulatory Action Is Lesser Of Firms’ Worries Amid Class-Action Blitz

Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years in today’s litigious climate, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics in New York. Speakers provided examples and tips for staying out of court.

FDA: “Extreme” Anti-Aging Claims Led To 2012 Warning Letters

A proliferation of “extreme” anti-aging cosmetic claims that crossed the line into drug territory led to FDA’s cluster of warning letters in 2012, according to Jennifer Thomas, director of the division of enforcement in the Center for Food Safety and Applied Nutrition’s office of compliance,

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel